Analysts have been eager to weigh in on the Healthcare sector with new ratings on Progyny (PGNY – Research Report), DaVita (DVA – Research Report) and Demant (WILLF – Research Report).
Progyny (PGNY)
KeyBanc analyst Scott Schoenhaus maintained a Buy rating on Progyny today and set a price target of $45.00. The company’s shares closed last Tuesday at $32.00.
According to TipRanks.com, Schoenhaus is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Progyny with a $49.00 average price target, a 58.0% upside from current levels. In a report issued on October 24, BTIG also maintained a Buy rating on the stock with a $45.00 price target.
See the top stocks recommended by analysts >>
DaVita (DVA)
In a report released yesterday, Lisa Bedell Clive from Bernstein maintained a Hold rating on DaVita, with a price target of $100.00. The company’s shares closed last Tuesday at $80.09.
According to TipRanks.com, Clive is ranked #6771 out of 8601 analysts.
Currently, the analyst consensus on DaVita is a Hold with an average price target of $114.50, a 46.3% upside from current levels. In a report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $112.00 price target.
Demant (WILLF)
In a report released today, Susannah Ludwig from Bernstein maintained a Buy rating on Demant, with a price target of DKK300.00. The company’s shares closed last Monday at $39.61.
According to TipRanks.com, Ludwig is ranked #7077 out of 8601 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Demant with a $43.18 average price target, a 9.0% upside from current levels. In a report issued on October 24, Deutsche Bank also initiated coverage with a Buy rating on the stock with a DKK318.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PGNY:
- Progyny, Inc. Announces Third Quarter 2023 Results
- ‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks
- The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their Families
- Progyny, Inc. Announces Details for Its Third Quarter 2023 Results Report
- Progyny price target lowered to $45 from $50 at BTIG
